Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

Brii Bio Announces Amubarvimab/romlusevimab Combination Received Approval From Nmpa As First Covid 19 Neutralizing Antibody Combination Therapy In China

Facebook Comments

Leave a Reply

CommentLuv badge